OA Structural Progression Effect Size Of 50% Is "High Hurdle," PhRMA Says

FDA's proposal that an osteoarthritis "delay in structural progression" claim be supported by a greater than 50% slowing of joint space narrowing is "too high a hurdle given the state of OA science," the Pharmaceutical Research & Manufacturers of America said in Sept. 14 comments on FDA's draft OA guidance.